Skip Nav Destination
Issues
1 June 2021
-
Cover Image
Cover Image
An X-ray crystal structure of auto-palmitoylation inhibitor VT105 bound to TEAD3. On page 986, researchers at Vivace Therapeutics report discovery and optimization of TEAD auto-palmitoylation inhibitors that selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma. These auto-palmitoylation inhibitors present an opportunity to treat cancers and other diseases that arise from abnormal inactivation of the Hippo signaling pathway. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
David M. Briere; Shuai Li; Andrew Calinisan; Niranjan Sudhakar; Ruth Aranda; Lauren Hargis; David H. Peng; Jiehui Deng; Lars D. Engstrom; Jill Hallin; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Kwok-Kin Wong; James G. Christensen; Peter Olson
Expanding the Repertoire for “Large Small Molecules”: Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers
Ahmed Hamed Salem; Zhi-Fu Tao; Orlando F. Bueno; Jie Chen; Shuang Chen; Rohinton Edalji; Steven W. Elmore; Keith M. Fournier; Kaid C. Harper; Richard Hong; Gary J. Jenkins; Jianguo Ji; Russell A. Judge; John C. Kalvass; Russell C. Klix; Yi-Yin Ku; Joel D. Leverson; Richard A. Marks; Kennan C. Marsh; Rajeev M. Menon; Chang H. Park; Darren C. Phillips; Yu-Ming Pu; Saul H. Rosenberg; Yeshwant D. Sanzgiri; Ahmad Y. Sheikh; Yi Shi; Deanne Stolarik; Ahmed A. Suleiman; Xilu Wang; Geoff G.Z. Zhang; Nathaniel D. Catron; Andrew J. Souers
In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
Sani H. Kizilbash; Shiv K. Gupta; Karen E. Parrish; Janice K. Laramy; Minjee Kim; Gautham Gampa; Brett L. Carlson; Katrina K. Bakken; Ann C. Mladek; Mark A. Schroeder; Paul A. Decker; William F. Elmquist; Jann N. Sarkaria
Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein–coupled Receptor 68
Takahiro Yamanaka; Norifumi Harimoto; Takehiko Yokobori; Ryo Muranushi; Kouki Hoshino; Kei Hagiwara; Dolgormaa Gantumur; Tadashi Handa; Norihiro Ishii; Mariko Tsukagoshi; Takamichi Igarashi; Akira Watanabe; Norio Kubo; Kenichiro Araki; Kazuo Umezawa; Ken Shirabe
Enhancing Proteotoxic Stress in Leiomyosarcoma Cells Triggers Mitochondrial Dysfunctions, Cell Death, and Antitumor Activity in vivo
Luca Iuliano; Sara Drioli; Ymera Pignochino; Claudia Maria Cafiero; Martina Minisini; Francesca D'Este; Raffaella Picco; Emiliano Dalla; Giorgia Giordano; Giovanni Grignani; Eros Di Giorgio; Fabio Benedetti; Fulvia Felluga; Claudio Brancolini
Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Jessica L. Christenson; Kathleen I. O'Neill; Michelle M. Williams; Nicole S. Spoelstra; Kenneth L. Jones; G. Devon Trahan; Jordan Reese; Elaina T. Van Patten; Anthony Elias; Joel R. Eisner; Jennifer K. Richer
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition
Larissa S. Carnevalli; Molly A. Taylor; Matthew King; Anna M.L. Coenen-Stass; Adina M. Hughes; Sigourney Bell; Theresa A. Proia; Yanjun Wang; Antonio Ramos-Montoya; Neha Wali; Danielle Carroll; Maneesh Singh; Michele Moschetta; Pablo Morentin Gutierrez; Cristina Gardelli; Susan E. Critchlow; Teresa Klinowska; Stephen E. Fawell; Simon T. Barry
Large Molecule Therapeutics
Novel TGFβ Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti–PD-L1 Immunotherapy
Nils Ludwig; Łukasz Wieteska; Cynthia S. Hinck; Saigopalakrishna S. Yerneni; Juliana H. Azambuja; Richard J. Bauer; Torsten E. Reichert; Andrew P. Hinck; Theresa L. Whiteside
Calicheamicin Antibody–Drug Conjugates with Improved Properties
Breanna S. Vollmar; Chris Frantz; Melissa M. Schutten; Fiona Zhong; Geoffrey del Rosario; Mary Ann T. Go; Shang-Fan Yu; Douglas D. Leipold; Amrita V. Kamath; Carl Ng; Keyang Xu; Josefa dela Cruz-Chuh; Katherine R. Kozak; Jinhua Chen; Zijin Xu; John Wai; Pragya Adhikari; Hans K. Erickson; Peter S. Dragovich; Andrew G. Polson; Thomas H. Pillow
A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization
Mirim Hong; Youngki Yoo; Miyoung Kim; Ju Yeon Kim; Jeong Seok Cha; Myung Kyung Choi; Uijin Kim; Kyungyong Kim; Youngsoo Sohn; Donggoo Bae; Hyun-Soo Cho; Seung-Beom Hong
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC
Hiroyuki Arai; Shu Cao; Francesca Battaglin; Jingyuan Wang; Natsuko Kawanishi; Ryuma Tokunaga; Fotios Loupakis; Sebastian Stintzing; Shivani Soni; Wu Zhang; Christoph Mancao; Bodour Salhia; Shannon M. Mumenthaler; Chiara Cremolini; Volker Heinemann; Alfredo Falcone; Joshua Millstein; Heinz-Josef Lenz
Cancer Biology and Translational Studies
Author Choice
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
Lindy Vernooij; Laurel T. Bate-Eya; Lindy K. Alles; Jasmine Y. Lee; Bianca Koopmans; Hunter C. Jonus; Nil A. Schubert; Linda Schild; Daphne Lelieveld; David A. Egan; Mark Kerstjens; Ronald W. Stam; Jan Koster; Kelly C. Goldsmith; Jan J. Molenaar; M. Emmy M. Dolman
Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases
Gregory C. Fox; Xinming Su; Jennifer L. Davis; Yalin Xu; Kristin A. Kwakwa; Michael H. Ross; Francesca Fontana; Jingyu Xiang; Alison K. Esser; Elizabeth Cordell; Kristen Pagliai; Ha X. Dang; Jothilingam Sivapackiam; Sheila A. Stewart; Christopher A. Maher; Suzanne J. Bakewell; James A.J. Fitzpatrick; Vijay Sharma; Samuel Achilefu; Deborah J. Veis; Gregory M. Lanza; Katherine N. Weilbaecher
Models and Technologies
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds